MedPath

Doconexent

Generic Name
Doconexent
Brand Names
Animi-3 With Vitamin D, Citranatal Harmony
Drug Type
Small Molecule
Chemical Formula
C22H32O2
CAS Number
6217-54-5
Unique Ingredient Identifier
ZAD9OKH9JC
Background

A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function. The amino-phospholipid DHA is found at a high concentration across several brain subcellular fractions, including nerve terminals, microsomes, synaptic vesicles, and synaptosomal plasma membranes .

Indication

Used as a high-docosahexaenoic acid (DHA) oral supplement.

Associated Conditions
Fredrickson classification type IV Hyperlipidemia, Fredrickson type IIb hyperlipidemia, Type III hyperlipidaemia
Associated Therapies
Nutritional supplementation
Clinical Trials
Related News

Alzheimer's Clinical Trial Update: New Data on Tau-Targeting Drugs and More

• Eisai presented Phase 1/2 data on E2814, an anti-tau drug, showing reduced levels of disease biomarkers in participants with mild to moderate genetic Alzheimer’s. • Roche terminated its agreement with UCB for beprenemab, an experimental tau-targeting antibody, after Phase 2 trial results showed it did not slow cognitive decline. • A Phase 2 trial of intranasal insulin and empagliflozin showed that insulin alone was associated with a small improvement in cognitive test performance in early Alzheimer’s patients.

CTAD 2024: Mixed Results for Alzheimer's Therapies Highlighted

• Eisai's E2814, an anti-tau drug, showed promise in reducing disease biomarkers in a Phase 1 trial involving participants with genetic Alzheimer's, warranting further studies. • Roche's trontinemab demonstrated effective amyloid reduction at high doses with a lower incidence of ARIA compared to other anti-amyloid antibodies in a Phase 1/2 trial. • UCB's beprenemab, a tau-targeting antibody, failed to slow cognitive decline in a Phase 2 trial, leading Roche to terminate their development and commercialization agreement. • Gene therapy LX001 from Lexeo Therapeutics showed early signs of success by increasing ApoE2 protein production and stabilizing amyloid levels in an ongoing Phase 1/2 study.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy